We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline has booked a 2 percent dip in revenues for the first quarter to £7.2 billion, after results were hit by a “significant currency impact” and lower sales of prescription drugs.
GlaxoSmithKline’s new chief executive Emma Walmsley has unveiled her strategy for the company, saying its pharma division must focus more on its key assets and deliver ‘full value’ from launches.